The concept of a “magic bullet” that would treat human disease, including cancer, without harming normal tissues resulted in a Nobel Prize for Paul Ehrlich in 1908. It wasn’t until 1975 when Georges Köhler and César Milstein described a method for producing monoclonal antibodies in large quantities that the concept of a magic bullet became a reality. Since then, the FDA has approved more than 40 antibody or antibody-derived biological entities for the treatment of oncology indications. Some of these antibodies e.g., the anti-PD-1 or anti-CTLA-4 antibodies, have transformed the outlook for patients with previously untreatable malignancies such as advanced melanoma.
Alongside the rapidly increasing number of targets that can be exploited for cancer treatment, we’ve made huge strides in our understanding of antibody production and engineering to make even more selective and effective biological therapeutics. Join us to hear from experts Drs. Katherine Vousden and Elizabeth Anderson as they share recent advances like phage display, CAR-T cells via bispecific T-cell engagers (BiTEs), and antibody-drug conjugates.
Katherine Vousden, PhD
Science Director, Large Molecules
Elizabeth Anderson, PhD
Scientific Director, Oncology
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.